Breast

Metastatic

HER2 +

2nd Line or Later

3rd Line or Later

**BRS0156**
Phase II
Multi-Center
Randomized
Open-Label Trial of BDC-1001 as Single Agent & in Combo w/ Pertuzumab in Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer Previously Treated / Trastuzumab Deruxtecan

**BRS0131**
Phase I/II
Zotatfin (eFT227) in Selected Advanced Solid Tumor Malignancies
Pi: Caswell-Jin
Sponsor: eFFECTOR Therapeutics, Inc.

**BRS0128**
Phase Ib/II
Open-Label Multicenter Randomized Umbrella Study Evaluating the Efficacy & Safety of Multiple Treatment Combinations in Breast Cancer (Morpheus- Breast Cancer)
New HER2+
Cohort Only
Pi: Telli
Sponsor: F. Hoffmann-La Roche Ltd

**KEY**
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Enrollment on Hold
- Immunotherapy